A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer | Future Oncology
The ASCENT study compared Sacituzumab Govitecan with standard chemotherapy for the treatment of metastatic triple negative breast cancer. Access a plain language summary of the study here:
Sacituzumab Govitecan (also known by the brand name TRODELVY®) is a new and available treatment for metastatic triple-negative breast cancer, or mTNBC for short. Metastatic breast cancer means the breast cancer has spread to other parts of the body. Triple negative means the breast cancer does not ...